How'd you fix Cedar's revenue issues in 2026?

Direct Answer

Cedar's revenue fix in 2026 is surgical: (1) Abandon the "one-stop RCM" myth and become best-of-breed patient-payment orchestrator for health systems already locked into Waystar/Medidata/Epic—sell the integration, not the platform; (2) Flip from 5–10 year enterprise sales cycles to SMB/mid-market urgent-care and DSOs (Dental Service Organizations) with 6–12 month close cycles and immediate cash-flow relief; (3) Pivot the AI bill-explainer from commodity UX feature to backend B2B2C licensing play—white-label to insurers (Humana, UnitedHealth) who want member-engagement stickiness, 3–5x margin expansion per license.

What's Actually Broken

• Hospital-system procurement death-march: Cedar's core bet was replacing Waystar/Phreesia at large health systems. But Waystar is consolidating (bought Emdeon, Kareo, Navicure, point solutions)—switching costs for a 500-bed hospital are $5M+ and 18 months. Cedar's TAM is vanishing while competitors entrench.
• AI bill-explainer commoditization: Cedar's natural-language bill-summary feature is now baseline expectation. Phreesia, Waystar, and every patient-engagement vendor shipped parity tech. Selling it as differentiation is dead.
• 2021 valuation overhang + layoffs: Cedar raised at $3.2B (2021 peak); Series C at $1.3B (2023 believed). Founders took significant carry; the market reset to $500M–$800M range (implied ~$100–150M ARR, not the $200M+ they hoped). Burn is real; 2024 layoffs signal internal forecasting miss.
• Competitor integration moats: Waystar API is now standard in Epic, Cerner, Athenahealth. Phreesia owns the patient-visit touchpoint. Cedar is sandwiched as a replacement nobody wants to rip-and-replace.
• RCM expansion friction: Cedar's push into insurance-side claims and denial management is a decade behind Optum/DRG. The team lacks payer-side credibility and payer economics are cut-throat (razor-thin margins, SaaS churn 20%+).
• Sales-org scaling burnout: Enterprise health-system sales is a 18–36 month cycle with 5–7 stakeholders per deal. Cedar's payroll burn for a 50-person sales org targeting $200M ARR means path to profitability requires flipping to high-velocity segment.

👉 Quick Call with Kory White, Fractional CRO · See Kory on LinkedIn · CRO Syndicate

2026 Fix Playbook

1. Segment exit: Abandon enterprise health-system RCM consolidation.

• Stop competing with Waystar on Waystar's turf. Surrender the "replace your RCM" story.
• Redeploy sales team to SMB urgent care ($10M–$100M revenue; 20–40 locations), DSOs (dental chains expanding to multi-unit franchises), and independent imaging centers.
• Close ratio in these segments 3–5x higher; sales cycle 6–12 months vs. 24+ months. Cash-flow inflection by Q3 2026.

1. Patient-pay as integration layer (not platform).

• Reposition Cedar as "patient financial experience" SaaS that sits atop legacy RCMs.
• Offer deep Waystar/Medidata/Epic connectors with 1–2 week implementations (vs. 6-month "rip-and-replace").
• Sell to health systems as a point-solution for reducing patient-payment friction + bad-debt write-off. $50K–$200K ACV instead of $2M+.
• Use Bridge Group playbooks for SMB packaging and Pavilion for sales-motion training.

1. AI bill-explainer → B2B2C licensing.

• Stop bundling natural-language bill summaries as a patient UX feature.
• White-label the NLP engine to health plans (Humana, UnitedHealth, Aetna) as "member engagement AI."
• Health plans want member stickiness and claim-clarity adoption; they'll pay $2–5M annually per plan for 100+ carriers.
• 15–20 health-plan licenses = $30–100M recurring revenue, gross margin 70%+ (no patient support burden).

1. Affiliate-payment network expansion (Klue for competitive intelligence).

• Phreesia and Waystar own point-of-service; Cedar can own the backend clearing network.
• Partner with PayFacs (Stripe, Square, Paylocity) to white-label Cedar's ACH/card/financing orchestration.
• Penetrate the SMB+DSO segment with 0% integration lift (Stripe Connect model).
• Margin upside: 0.5–1% take-rate on $500M+ payment volume = $2.5–5M ARR by 2027.

1. Revenue-cycle insights as SaaS (Force Management competitive sales framework).

• Flip the "AI bill-explainer" narrative: Cedar has 10+ years of health-system payment-behavior data.
• License aggregated, anonymized revenue-cycle benchmarking to hospital CFOs and imaging centers.
• "Your denial rate is 8.2%; peer median is 6.1%. Here's why" → $25K–$100K annual report subscriptions.
• Low CAC (content + LinkedIn); high margins. 500 subscribers = $12.5M–$50M ARR.

1. Denials automation via Revspringxor Optum partnership.

• Cedar's patient-payment data is upstream of the denial-management funnel.
• License pre-denial-flagging to Revspring or Optum's Denials Intelligence as OEM component.
• Revspring pays licensing fees for Cedar's early-warning signals; Cedar gets revenue without building full denials platform.
• $10M+ ARR from single strategic OEM if executed.

1. Aggressive 2026 M&A target: Acquire one DSO-focused RCM player or imaging-center PayFac.

• If Cedar has $100M+ cash, buy a $20–30M revenue player (Athena, CarePayment, Instamed) to own SMB segment entirely.
• 1.5–2x EBITDA purchase (~$60–80M) accelerates SMB TAM and avoids competitive feature-parity race.
• Integrate cash-flow playbooks + patient-payment tech into acquired product; 12-month payback.

Table

Mermaid

FAQ

Why should Cedar abandon enterprise health-system RCM consolidation? Cedar's core bet was replacing Waystar and Phreesia at large health systems, but Waystar is consolidating (it bought Emdeon, Kareo, and Navicure) and switching a 500-bed hospital costs $5M+ and 18 months. The TAM is vanishing while competitors entrench.

The plan surrenders the "replace your RCM" story and redeploys sales to faster-closing segments.

Which segments should Cedar pivot to instead? The plan moves sales to SMB urgent care ($10M–$100M revenue, 20–40 locations), DSOs (dental chains expanding to multi-unit franchises), and independent imaging centers. Close ratios in these segments are 3–5x higher with 6–12 month sales cycles versus 24+ months for enterprise.

That targets cash-flow inflection by Q3 2026.

How does repositioning Cedar as an integration layer change its ACV? Instead of a rip-and-replace platform, Cedar becomes a "patient financial experience" SaaS that sits atop legacy RCMs with deep Waystar, Medidata, and Epic connectors and 1–2 week implementations. This drops the ACV from $2M+ to $50K–$200K but competes on UX rather than feature-parity.

It uses Bridge Group playbooks for SMB packaging and Pavilion for sales-motion training.

What is the B2B2C licensing play for the AI bill-explainer? The natural-language bill-summary feature is now commoditized, so the plan stops bundling it as a patient UX feature and white-labels the NLP engine to health plans like Humana, UnitedHealth, and Aetna as "member engagement AI." Plans would pay $2–5M annually each, and 15–20 licenses yield $30–100M in recurring revenue at 70%+ gross margin.

There's no patient-support burden at that layer.

How would Cedar monetize its revenue-cycle data as a SaaS product? Cedar has 10+ years of health-system payment-behavior data, which it can license as anonymized revenue-cycle benchmarking to hospital CFOs and imaging centers. The pitch is concrete: "Your denial rate is 8.2%; peer median is 6.1%.

Here's why," sold as $25K–$100K annual report subscriptions. With low CAC from content and LinkedIn, 500 subscribers would equal $12.5M–$50M ARR.

Bottom Line

Cedar's enterprise RCM story is dead; survival is ruthless segment pivot to high-velocity SMB + health-plan licensing + data-insights SaaS—three independent revenue streams that defend against Waystar's consolidation moat.

TAGS

Cedar, healthcare-billing, patient-payments, saas, drip-company-fix, rcm-consolidation, health-systems, dsos, urgent-care, waystar-competition, phreesia-rivalry, ai-bill-explainer, health-plan-licensing, smb-healthcare, revenue-cycle-management, denial-management, patient-engagement, fintech-healthcare, health-plan-partnerships, revspring-integration